专利检索 ap:("The Research Foundation of the State University of New York" OR "Cohen, Stanley N.") AND inv:"CARTER, Carol" 第 1 页

1.

发明授权
TSG101 AS INHIBITOR OF HIV PRODUCTION 有权
标题翻译： TSG101作为抑制剂HIV-生产

公开(公告)号：EP1401490B1

公开(公告)日：2008-07-16

申请号：EP02731876.5

申请日：2002-05-21

申请人： The Research Foundation of the State University of New York , Cohen, Stanley N.

发明人： COHEN, Stanley N., Dept. of Genetics School of Medicine , CARTER, Carol , GOFF, Arthur , EHRLICH, Lorna

IPC分类号： G01N33/50 , G01N33/569 , G01N33/68 , C07K14/16 , C07K14/47

CPC分类号： G01N33/502 , A61K38/1709 , C07K14/005 , C07K14/4702 , C07K2319/00 , C12N2740/16222 , G01N33/5008 , G01N33/56983 , G01N33/56988 , G01N33/6878 , G01N2333/16 , G01N2333/161 , G01N2500/02 , G01N2500/10 , G01N2500/20

摘要： The present invention provides methods for identifying peptides in a mammalian Tsg101 protein that binds to the PTAPP motif or L domain of human immunodeficiency virus type I (HIV-1). Such peptides can be used to inhibit Tsg101-HIV Gag binding, and is therefore effective in reducing HIV particle production. The invention also provides the peptides identified by the method of the invention and to method of using such peptides for treating HIV infection.

2.

发明公开
TSG101 AS INHIBITOR OF HIV PRODUCTION 有权
标题翻译： TSG101作为抑制剂HIV-生产

公开(公告)号：EP1401490A1

公开(公告)日：2004-03-31

申请号：EP02731876.5

申请日：2002-05-21

申请人： THE RESEARCH FOUNDATION OFSTATE UNIVERSITY OF NEW YORK , Cohen, Stanley N.

发明人： COHEN, S.N.,Dept of Genetics School of Medicine , CARTER, Carol , GOFF, Arthur , EHRLICH, Lorna

IPC分类号： A61K39/21 , A01N43/04 , G01N33/53 , C12Q1/68 , C12N15/00 , C12N15/64 , C12N5/00 , C12N15/63

CPC分类号： G01N33/502 , A61K38/1709 , C07K14/005 , C07K14/4702 , C07K2319/00 , C12N2740/16222 , G01N33/5008 , G01N33/56983 , G01N33/56988 , G01N33/6878 , G01N2333/16 , G01N2333/161 , G01N2500/02 , G01N2500/10 , G01N2500/20

摘要： The present invention provides methods for identifying peptides in a mammalian Tsg101 protein that binds to the PTAPP motif or L domain of human immunodeficiency virus type I (HIV-1). Such peptides can be used to inhibit Tsg101-HIV Gag binding, and is therefore effective in reducing HIV particle production. The invention also provides the peptides identified by the method of the invention and to method of using such peptides for treating HIV infection.